Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasRaphaël Itzykson, Olivier Kosmider, Thomas Cluzeau et al.|Leukemia|2011Cited by 464
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*Sophie Georgin‐Lavialle, Thomas Cluzeau, Maxime Samson et al.|British Journal of Dermatology|2021Cited by 414
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patientsThomas Cluzeau, Patrick Auberger|Oncotarget|2012Cited by 83
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 casesÈve Zakine, C. Deligny, Loula Papageorgiou et al.|Journal of the American Academy of Dermatology|2022Cited by 67
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 <sup>+</sup> Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic LeukemiaJean‐Baptiste Robin, Thibaut Leguay, Marc Delord et al.|Journal of Clinical Oncology|2024Cited by 33